ESPAC-4 logo

ESPAC-4

Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers.

ESPAC-4

Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers.
Funding CR:UK
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 13-Oct-2008

Long term survival following resection for pancreatic cancer still needs to be improved. Adjuvant 5-FU/FA demonstrates significant improvement in overall survival following Surgery, adjuvant gemcitabine demonstrates a survival advantage following surgical resection for pancreatic cancer. Gemcitabine plus capecitabine improves survival in patients with advanced pancreatic cancer compared with single agent gemcitabine

Publications

  • Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med. 2019 Mar 14. pii: S0755-4982(19)30074-0. doi: 10.1016/j.lpm.2019.02.025. [Epub ahead of print] PubMed PMID: 30879894
    1. 10.1016/j.lpm.2019.02.025